View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
January 11, 2022updated 21 Mar 2022 7:22am

2021 saw a 52% drop in pipeline Anesthesia and Respiratory Devices products globally

By Carmen

The number of pipeline Anesthesia and Respiratory products in 2021 saw a 52% drop globally when compared to Anesthesia and Respiratory pipeline products in 2020, according to GlobalData’s pipeline products database. This compares to an 15% rise for all pipeline medical devices in 2021 compared to 2020.

The global Anesthesia and Respiratory Devices market was worth $16.34bn in 2020 and is expected to reach $18.94bn by 2025, according to GlobalData’s analysis.

Anesthesia and Respiratory Devices pipeline products by categories: Respiratory Devices has the most devices

Looking at the device categories of pipeline products, Respiratory Devices accounted for the largest proportion (49.02%) in 2021, followed by Diagnostic and Measurement Devices (23.53%) and Airway Management (20.59%).

Of the global medical devices market value, the Anesthesia and Respiratory Devices market held a 3% share worth $16bn in 2021 and is expected to reach $18.94bn by 2025.

Anesthesia and Respiratory Devices development activity: Advanced stage of development leads

Devices at an advanced stage of development (in clinical trials, in the approval process, already approved in Europe or the rest of the world) accounted for 45.63% of medical devices in 2021, compared with 38.97% in 2020. The number of devices at the In Approval stage declined by 64% in 2021, when compared with 2020.

The In Approval stage is considered to be the period where the manufacturer is waiting for final approval from regulators, following completion of the required development steps.

A decrease in products awaiting approval would indicate less new products entering the market in the coming months, while an increase indicates more devices entering the market, posing a market share threat to existing marketed devices.

North America tops pipeline Anesthesia and Respiratory Devices products activity

Comparing the number of pipeline Anesthesia and Respiratory Devices products activity in different regions of the globe, North America held the top position (55%) during 2021, followed by Asia-Pacific (28%), and Europe (15%).

On a country level, the US had the most pipeline Anesthesia and Respiratory Devices during the year, representing the largest share (54%) of Anesthesia and Respiratory pipeline products. In second place was India (12%), followed by China (8%).

New pipeline Anesthesia and Respiratory medical devices: Expected to be approved by 2025

According to GlobalData, approximately 49% of pipeline Anesthesia and Respiratory Devices in 2021 were expected to receive regulatory approval by the end of 2025. The leading categories for devices expected to receive regulatory approval by the end of 2025 was Pulse Oximeter Systems, at 6% of devices. Differences in regulatory approval timelines reflect the stage of development for a device, the device complexity or risk categorization (or device class) or if there are changes in regulatory oversight.

Fisher & Paykel Healthcare Corporation Ltd tops Anesthesia and Respiratory Devices development in 2021

According to GlobalData, top ten medical device companies accounted for 21.57% of pipeline Anesthesia and Respiratory Devices activity during 2021. The leading company for developing Anesthesia and Respiratory Devices was Fisher & Paykel Healthcare Corporation Ltd with 2.94%, followed by All India Institute of Medical Sciences at 2.94%.

Companies launching new medical devices are more likely to disrupt existing market share or are better able to defend existing share.

Company-developed pipeline products lead Anesthesia and Respiratory Devices in development

Looking at the share of activity in terms of Anesthesia and Respiratory pipeline products developers, company-developed pipeline products accounted for a 71% share of the Anesthesia and Respiratory medical devices market, while institute-developed pipeline products held the remaining share.

The monthly average for 2021 saw company-developed Anesthesia and Respiratory pipeline products account for 71% of pipeline products and institute-developed pipeline products account for 29%.

Methodology
The medical devices pipeline data used in this article were extracted from Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database covers all medical devices which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Pipeline products are covered from various authenticated sources like company websites, SEC filings, conference presentations, analyst presentations, news releases, grants etc. The information is collected by following systematic research techniques and proprietary methodology.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network